Douglas Flora: I’ll be kicking off the NCI’s new and groundbreaking “AI and Cancer Webinar Series”
Douglas Flora, Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, shared a post on LinkedIn:
“Thrilled to announce I’ll be kicking off the NCI’s new and groundbreaking AI and Cancer Webinar Series. We’re kicking off 2025 by diving deep into how AI is transforming cancer care and research.
Thank you to Dr. Daoud Meerzaman and Kayla Strauss for the kind invitation to participate in this innovative and important series.
Join me as we explore this fascinating intersection of technology and health care. We’ll unpack everything from essential AI concepts to real-world applications in oncology.
Here’s what we’ll cover:
- Demystifying AI terminology in health care.
- The fascinating evolution of AI in cancer research.
- How AI is revolutionizing clinical trials and diagnostics.
- Game-changing AI applications in drug discovery.
- What’s next: Future possibilities and important considerations.
Register to tune in here.
This is just the beginning. CBIIT and NCI’s Division of Treatment and Diagnosis AI working group have crafted an incredible series that will tackle crucial questions:
- Practical applications across diagnosis, treatment, and omics research.
- Navigating the legal and ethical landscape.
- Building a stronger, AI-ready cancer research community through collaboration and strategic funding.
Don’t miss this opportunity to be part of the conversation shaping the future of cancer care.
Looking forward to seeing you there and hearing your insights.”
Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health and the Leader of the AI and HealthCare Team for the Cincinnati AI Catalyst (CaiC).
As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.
More posts featuring Douglas Flora.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023